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Abstract
Background: Early diagnosis and treatment of the newborn infant with suspected sepsis are essential to prevent
severe and life threatening complications. Diagnosis of neonatal sepsis is difficult because of the variable and
nonspecific clinical presentation. Therefore, many newborns with nonspecific symptoms are started on antibiotic
treatment before the presence of sepsis has been proven. With our recently published single-centre intervention
study we were able to show that Procalcitonin determinations allowed to shorten the duration of antibiotic
therapy in newborns with suspected early-onset sepsis.
Methods/Design: The study is designed as randomized controlled international multicenter intervention trial on
the efficacy and safety of Procalcitonin guided treatment. Term and near-term infants (gestational age ≥ 34 0/7
weeks) with suspected sepsis in the first 3 days of life requiring empiric antibiotic therapy will be included. The
duration of antibiotic therapy in the standard group is based on the attending physician’s assessment of the
likelihood of infection (infection unlikely, possible, probable or proven). In the Procalcitonin group, if infection is
considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive Procalcitonin values
are within the normal range. Co-primary outcome measures are the duration of antibiotic therapy (superiority
aspect of the trial) and the proportion of infants with a recurrence of infection requiring additional courses of
antibiotic therapy and/or death in the first month of life (safety of study intervention, non-inferiority aspect of the
trial). The number of infants to be included equals 800 per arm. With these numbers the power of the study to
demonstrate superiority for duration of antibiotic therapy as well as non-inferiority regarding safety, i.e. excluding a
disadvantage difference larger than 2% for the experimental arm, will both be greater than 80%.
Discussion: Benefit of the study is a possible limitation of unnecessary use of antibiotics. The results of our first
study suggest that there is a low risk on discontinuing antibiotic treatment too early, resulting in the development
of a neonatal infection with its morbidity and mortality.
Trial registration: This trial is registered in the U.S. National Institutes of Health’s register, located at http://www.
clinicaltrials.gov. (NCT00854932).
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Infections are the single largest cause of neonatal deaths
globally [1]. Based on the onset, neonatal sepsis is classi-
fied into two major categories: early onset sepsis, which
usually presents with respiratory distress within 72 hours
of age and late onset sepsis that usually presents with
septicemia after 72 hours of age. Sepsis in neonates is a
significant contributor to morbidity and death, with mor-
tality rates varying from 3% to as high as 50% in some
series, especially with gram-negative pathogens [2-6].
The incidence of early-onset sepsis in term neonates in
The Netherlands 2003-2006 is approximately 0.6% [7].
Early diagnosis and treatment of the newborn infant
with suspected sepsis are essential to prevent severe and
life threatening complications. In contrast to the clear
and valuable therapeutic options, the diagnosis of sus-
pected early-onset neonatals e p s i si sc h a l l e n g i n g .T h e
early signs of sepsis in the newborn are non-specific.
Therefore, many newborns with nonspecific symptoms
undergo diagnostic studies and the initiation of treatment
before the presence of sepsis has been proven. Blood cul-
ture is currently the gold standard for the diagnosis of
sepsis. However, in addition to the fact that culture
reports are available only after 48-72 hours, blood cul-
tures are frequently false negative due to the small
amount of blood that can be drawn from neonates [8].
The reliability of most laboratory markers, including
white blood cell count (WBC), C-reactive protein (CRP),
Procalcitonin (PCT) and IL-6 for the diagnosis of neona-
tal infection has been assessed in highly diverse groups of
ill neonates with a mixture of diagnoses and conditions
and has yielded variable results [9]. If culture results
come back negative after 48-72 hours, the clinician has
to decide whether to provide continued treatment.
In the era of multidrug resistance, it is mandatory to
avoid unnecessary use of antibiotics to treat non-
infected infants. In addition, the intravenously adminis-
tration of antibiotics necessitates admission of the
neonate to the hospital and thereby separation of
mother and child in this delicate period of life. Thus
rapid diagnostic test(s) that differentiate infected from
non-infected infants, particularly in the early newborn
period, have the potential to make a significant impact
on neonatal care. In an effort to reduce the use of anti-
microbial agents in neonates, clinical studies have been
undertaken using the biomarker CRP to safely influence
the length of antimicrobial therapy [10,11]. Thus far, no
evidence has been presented that using CRP can make
an impact on the length of antimicrobial therapy.
Another biomarker that has been discovered more
recently, PCT, is proven to be a good marker of severe,
invasive bacterial infections in children. All studies on
severe, invasive bacterial infections in children report
higher sensitivities and specificities of PCT than for
CRP [12-16]. PCT is a 116-aminoacid peptide and one
of the precursors of calcitonin. The physiological func-
tion of calcitonin remains unknown. No disorders attri-
butable to either an excess or a deficiency of calcitonin
have been identified. Most microbial infections induce a
ubiquitous increase in CALC1 gene expression and a
subsequent release of calcitonin precursors from all tis-
sues and cell types throughout the body [17]. In bacter-
ial infections, PCT increases from concentrations in the
picogram range (below the detection level of current
PCT assays) to plasma concentrations ranging from 1 to
1000 ng/ml. This increase often correlates with the
severity of the disease and with mortality [18-21].
Increases in PCT occur more rapidly than increases in
CRP. PCT can be detected in the plasma 2 hours after
the injection of endotoxins. Within 6-8 hours, PCT con-
centrations rise and a plateau is reached after approxi-
mately 12 hours [22]. CRP can be detected in the
plasma after 12 h and reaches a plateau after 20-72
hours. PCT and CRP decrease to their normal values
after 2-3 days and 3-7 days, respectively [23-25].
The use of PCT as a marker of neonatal bacterial
infection is complicated by several factors. First, infants
with respiratory distress syndrome, hemodynamic fail-
ure, perinatal asphyxia, intracranial hemorrhage, pneu-
mothorax, or after resuscitation have raised serum PCT
concentrations that do not differ from those of septic
neonates up to 48 h after onset of clinical signs of dis-
tress or infection [26-28]. Second, a physiological
increase of PCT has been reported up to 48 h post par-
tum [29]. Third, prepartum and intrapartum administra-
tion of antibiotics may affect PCT concentrations in the
umbilical cord [30], and postnatal administration of
antibiotics will decrease PCT concentrations more
rapidly than CRP concentrations [31,32]. When these
pitfalls are taken into account, PCT performs better
than CRP in diagnosing neonatal bacterial infection.
Chiesa et al developed a nomogram for PCT [33] and
Assumma and colleagues performed a longitudinal study
on PCT values in healthy neonates [34]. In his findings
Chiesa was able to report two major differences in
between healthy and septic neonates which formed the
basis of his nomogram. Firstly, the level of elevation in
PCT was much higher in septic neonates versus healthy
newborns and secondly, the absence of a decrease of
PCT values after the initial cytokine release post-partum
is indicative of a bacterial infection. With all PCT values
being increased during the first two days of life, a refer-
ence range covering this time period with intervals of
several hours is a tool to identify septic neonates. The
adult reference ranges apply from three days after birth.
Using PCT in this manner has been proven extensively
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sepsis [35-39].
In recent years a novel indication for the use of PCT
has been discovered, related to its described high nega-
tive value. It has been reported in many interventional
trials [40-44] that a low PCT indicates the absence of a
need for antimicrobial therapy. In several countries the
recent adult intensive care guidelines have been altered
to the extent that PCT has displaced CRP in the recom-
mendations [45,46]. Applying this principle to neonatol-
ogy, we performed a single-centre intervention trial in
Lucerne, Switzerland that showed that serial PCT deter-
minations allowed to shorten the duration of antibiotic
therapy in term and near-term infants with suspected
early-onset sepsis [47]. This study is designed to test the
reliability of a PCT-based strategy in a larger cohort of
neonates.
Methods/Design
The purpose of this trial is to evaluate whether PCT
measurements are able to reduce antibiotic usage in sus-
pected neonatal early-onset sepsis by reducing the dura-
tion of antibiotic treatment with unchanged outcome.
The study is designed as randomized open controlled
international multicenter intervention trial on the effi-
cacy (superiority aspect) and safety (non-inferiority
aspect) of PCT guided treatment.
Outcome measures
Co-primary outcome measures are the duration of anti-
biotic therapy and the proportion of infants with a
recurrence of infection requiring additional courses of
antibiotic therapy (within 72 hours after ending antibio-
tic therapy) and/or death in the first month of life
(safety of study intervention). A secondary outcome
measure is the length of hospitalisation stay.
Inclusion/Exclusion criteria
Inclusion criteria: Term and near-term infants with a
gestational age ≥ 34 0/7 weeks, age 0-3 days of life, sus-
pected sepsis in the first 3 days requiring empiric anti-
biotic therapy, parental consent. Exclusion criteria are
severe congenital malformations and surgical procedures
before or during the study. In case of surgical proce-
dures during this trial patients will be excluded from the
study and its analyses. These children will be treated by
current protocols of care, including protocols for anti-
biotic therapy. Patients are not allowed to enter the trial
for a 2
nd time.
Patients will be randomized between t = 0 and t = 12
h after the initiation of antibiotic treatment. Part of the
neonates will be eligible for inclusion immediately after
birth. Since it is not always possible to ask informed
consent from parents immediately after a child is born,
this timeframe for randomization of 12 hours is neces-
sary. Randomization will be to either a standard treat-
ment based on conventional laboratory parameters
(standard group) or to PCT-guided treatment (PCT
group) blocked by centre: Randomization is done by
drawing group assignment cards in opaque sealed envel-
opes (Switzerland) and by computer based digital rando-
mization (The Netherlands).
Statistical analyses
This trial is designed to exclude a difference in the rates
of re-infection or death greater than 2% (non-inferiority
aspect of the trial). Assuming a 2% reinfection/death
rate in each group, 770 patients are required per arm
for a power of 80% at one-sided alpha of 0.025. Based
on our data of the study in Lucerne [47], with this num-
ber of patients a difference between mean antibiotic
therapy durations of 10 hours can be detected at two-
sided alpha of 0.05 with a power of 95% (superiority
aspect of the trial). To allow for some unevaluable cases
800 per group will be included.
Primary analyses: The two-sided 95% confidence
interval for the difference (experimental - control) in
re-infection/death rates will be calculated for the total
randomized arms and if this difference excludes +2%,
non-inferiority is considered to be shown [48]. Compari-
son of durations of antibiotic therapy will be done using
the Mann-Whitney test with stratification by centre.
Any patients dying will be considered as the worst out-
come in this evaluation and their duration will be set at
the highest duration found. All analyses will be done
according to the intention-to-treat principle and will be
done with stratification by centre. A per-protocol analy-
sis, excluding patients with major protocol violations,
will also be done.
Secondary analysis: Exploratory analysis of primary
endpoints regarding the relations with and clinical out-
comes assessed at T = 24-72 h will be done using logis-
tic regression or Anova. In the Anova the duration’s
antibiotic treatment will be transformed logarithmically.
All tests are two-sided and p = 0.05 is the limit of sig-
nificance. These analyses will be informal only because
it cannot be excluded that the ratings of clinical out-
comes at T = 24-72 h are influenced by the PCT results
in the PCT-group. In a secondary analysis reinfection/
deaths rates will be compared between treatment arms
using random effects logistic regression allowing for
centre as a random factor.
Laboratory examinations
Complete blood counts and CRP concentrations are
obtained in all patients. Serial PCT measurements are
performed in all patients of the PCT group and if blind-
ing for the PCT results of the standard group is feasible
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stopped by ending of antibiotic therapy. Blood sampling
will be limited to normal frequencies already used in
daily practice for neonatal care. This means that for this
trial blood will collected at time points 0 (moment of
inclusion and start point of antibiotic therapy), 24 h (+/-
6 h) after inclusion, between 36 to 72 h after inclusion
and then 24-48 hourly until end of antibiotic therapy.
One additional sample will be collected in the PCT
group 12 h (+/- 6 h) after inclusion. With the exception
of the one additional sample in the PCT group, no addi-
tional punctures will be done for research purposes.
Procalcitonin will be measured on the automated
Kryptor platform, supplied by the firm BRAHMS AG of
Hennigsdorf, Germany, via the Roche Elecsys BRAHMS
procalcitonin assay. The BRAHMS Kryptor sensitive
procalcitonin will be applied on this platform using
Time Resolved Amplified Cryptate Emission (TRACE)
technology. This assay is based on a polyclonal antibody
against calcitonin and a monoclonal antibody against
katacalcin, which binds to the calcitonin and katacalcin
sequence of the calcitonin prohormone. The test is con-
sidered a homogeneous immunoassay (sandwich princi-
ple) and is validated on serum and plasma (EDTA and
heparin) matrix. The direct measuring range of the
assay is from 0.02-50 ng/ml, with automated dilution
extending the upper range to 1.000 ng/ml. The Func-
tional Assay Sensitivity (FAS) is 0.06 ng/ml. Procedure
time of the assay is very short at 19 minutes. The
needed sample volume is limited to 50 micro litres. The
Roche Elecsys BRAHMS procalcitonin assay equally uses
an immunoassay based on a sandwich principle based
on a polyclonal antibody against calcitonin and a mono-
clonal antibody against katacalcin, which binds to the
calcitonin and katacalcin sequence of the calcitonin pro-
hormone. The direct measuring range of the assay is
from 0.02-100 ng/ml. The Functional Assay Sensitivity
( F A S )i s0 . 0 6n g / m l .P r o c e d u r et i m eo ft h ea s s a yi sa l s o
very short at 18 minutes. The needed sample volume is
limited to 30 micro litres. The assay is validated on
serum and plasma (EDTA and heparin) matrix. CRP
and all other requested laboratory assays will be mea-
sured on the routine analyzers of the various sites and
will be made available to the physician through the rou-
tine laboratory systems in place.
Procalcitonin-guided decision making
The normal age-adapted PCT ranges according to our
previous study are shown in Figure 1. To provide a mar-
gin of safety, the maximal normal value of PCT is
defined as 10 ng/ml (18-36 hours of life) which, accord-
ing to the literature is about 50% of the highest PCT
concentrations measured in neonates with respiratory
distress not related to infection [33].
At time-point T = 24-72 h (one time-point between
24-72 h after start of antibiotic therapy: time-point of
positive culture result or time-point of early stop of
antibiotic therapy (less than 72 h of therapy) or 72 h
after start of therapy) neonates will be assessed and
divided into categories of risk classification (Table 1 and
2): infection proven (category 1), infection probable
(category 2), infection possible (category 3), and infec-
tion unlikely (category 4). The treating physician will
decide in which risk classification a neonate belongs.
Expected distribution based on the results of our first
study [47]: Category 1 50%, Category 2 30-35%, Cate-
gory 3 and 4 15-20%.
The duration of antibiotic therapy in the standard
group is based on the attending physician’s assessment
of the risk classification during hospitalisation: in cate-
gory 4 patients, antibiotics are given for 2 - 3 days, in
c a t e g o r y3p a t i e n t sf o r5-7d a y s .I nt h eP C Tg r o u p ,i f
infection is considered to be unlikely or possible, anti-
biotic therapy is discontinued when two consecutive
PCT values are within the normal range (Figure 1 Table
3). Antibiotic therapy can be continued despite fulfilled
PCT criteria at the discretion of the attending physician.
These diversions from the stopping rules will be
reported for further analysis. If infection is proven (cate-
gory 1) or considered to be probable (category 2) anti-
biotics are given for 7 - 21 days in both groups.
Follow up
Patients with a recurrent infection will not enter the
study for a second time. Recurrent infections will be
analysed for focus and relapse of previous infection and
will be treated at the physician’s discretion. Recurrent
infections in this trial will be defined as a new infection
occurring within 72 hours after stopping antibiotic ther-
apy for the initial infection. Any recurrent infection will
be reported immediately to the steering committee.
Follow-up of the patients will be performed as in
standard practice. Parents of discharged patients have
24 hours/day, 7 days/week access to the hospital and to
contact a paediatrician on call. Phone numbers to con-
tact the department will be provided upon discharge of
the child. A follow-up interview after 1 month will be
done with questions about undercurrent illness, physi-
cian visits, medications and hospitalisations.
Adverse events
All serious adverse events will be reported to the princi-
pal investigator within 24 hours after their occurrence.
Also the data and safety monitoring board and the ethi-
cal committee that approved the protocol will be
informed by the principal investigator, according to the
requirement of the ethical committee. All adverse events
will be followed until they have abated, or until a stable
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and safety monitoring board will be blinded to the
assigned intervention arm of the patient. At any time
the members of this board can ask to be unblinded by
requesting the treatment code from the independent
statistical centre.
Data collection and management
All data are collected in the neonatal intensive care
department or pediatric ward. The medical history and
used medication can be obtained from the patient’s
medical record. All collected data will be stored anon-
ymously in the study database. Data management will
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Figure 1 Normal age-adapted PCT ranges. Grey boxes = age-adapted normal range [47].
Table 1 Risk of infection classification categories
Category 4:
Low risk (Infection unlikely)
One abnormal finding:
- pre/perinatal risk factor*, OR
- suspect clinical symptom*, OR
- abnormal laboratory examination*
Category 3:
Intermediate risk (Infection
possible)
Two abnormal findings:
- pre/perinatal risk factors*, AND/OR
- suspect clinical symptoms*, AND/OR
- abnormal laboratory examinations*
Category 2:
High risk (Infection probable)
Three abnormal findings:
- pre/perinatal risk factors*, AND/OR
- suspect clinical symptoms*, AND/OR
- abnormal conventional laboratory examinations*
Category 1:
Proven infection
≥ 1 abnormal finding (pre/perinatal risk factors, clinical symptoms, laboratory examinations) AND a positive
culture
The assessment of risk of infection classification is independent of serum PCT levels.
* See assessment guidelines (Table 2)
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of the participating center. The subjects will be identi-
fied by a trial identification number. Data base integrity
and data safety as well as privacy are warranted by the
participating research hospitals. Source data verification
will be conducted by an independent Data Monitor.
An independent data- and safety monitoring commit-
tee is responsible for the ongoing conduct of the study,
based on unbiased and independent review of efficacy
and safety data. Dr. R. Oostenbrink, paediatrician and
clinical epidemiologist, Erasmus MC-Sophia, Rotterdam
and Prof. E. Lesaffre, statistician at Erasmus MC will
serve as members from The Netherlands and Prof.
G. Schubiger, neonatologist and head of the local ethical
committee in Lucerne and Dr. C. Hagmann, consultant
neonatologist at the University Hospital in Zurich from
Switzerland. The committee assesses the progress of the
trial, and the safety data and advises whether to con-
tinue, modify or stop the trial every 3 months. The
DMC charter informs about purpose, composition,
responsibilities and structure of the committee. The
board will operate under strict confidentiality.
Ethical approval and trial registration
For this trial a nationwide ethical approval was
requested for The Netherlands and local ethical
approval was requested for all participating centres by
their local ethical committee. Further participating study
centers outside Switzerland and The Netherlands have
to request approval by their ethical committee and to
present the approval to the steering committee of the
study. This trial will be conducted in accordance with
the ethical guidelines of the World Medical Associa-
tion’s declaration of Helsinki Ethical Principles for Med-
ical Research Involving Human Subjects as adopted by
the 18th WMA General Assembly, Helsinki, Finland,
June 1964, and amended by the 29th WMA General
Assembly, Tokyo, Japan, October 1975; 35th WMA
General Assembly, Venice, Italy, October 1983; 41st
WMA General Assembly, Hong Kong, September 1989;
48th WMA General Assembly, Somerset West, Republic
of South Africa, October 1996; 52nd WMA General
Assembly, Edinburgh, Scotland, October 2000; 53th
WMA General Assembly, Washington 2002 (Note of
Clarification on paragraph 29 added); 55th WMA Gen-
eral Assembly, Tokyo 2004 (Note of Clarification on
Paragraph 30 added); 59th WMA General Assembly,
Seoul, October 2008. Also, this trial will comply with
the regulations set forth by the Medical Research Invol-
ving Human Subjects Act (WMO) and other guidelines,
regulations and Acts that apply.
This trial is registered in the U.S. National Institutes
of Health’s register, located at http://www.clinicaltrials.
gov. under number NCT00854932.
Discussion
It is essential for observational studies to compare new
markers with the gold standard. The gold standard for the
diagnosis of neonatal early-onset sepsis, i.e. a positive
blood culture is often unreliable because of the frequent
use of intrapartum antibiotics or insufficient amounts of
blood available for culture [8]. Therefore, the problem of
all observational studies of neonatal early-onset sepsis is
the definition of sepsis. An intervention study offers a
valuable alternative because the calculation of the main
results is independent of the definition of sepsis. A control
Table 2 Assessment guidelines
Pre/perinatal risk factors Mother group B streptococcus (GBS) positive
Maternal prolonged rupture of membranes (PROM) > 18 h
Maternal chorioamnionitis (fever >38.5°, fetal tachycardia)
Birth before 35 weeks of gestational age
6 groups of suspect clinical signs and symptoms Respiratory distress/apnea
(signs and symptoms of one group = one abnormal finding) Tachycardia/bradycardia
Arterial hypotension/poor perfusion
Hypothermia/hyperthermia
Seizure/floppy infant/irritability/lethargy/poor feeding
Vomiting/feeding intolerance/ileus
Conventional laboratory examinations White blood cell count < 5 G/L
CRP > 10 mg/L
Table 3 Duration of antibiotic therapy
Standard
group
PCT group
Category 1
and 2
7 - 21 days 7 - 21 days
Category 3 5 - 7 days at least 24 hours, stop after 2
consecutively
negative PCT-values
Category 4 36 - 72 hours at least 24 hours, stop after 2
consecutively
negative PCT-values
Stocker et al. BMC Pediatrics 2010, 10:89
http://www.biomedcentral.com/1471-2431/10/89
Page 6 of 8group is necessary to demonstrate that results from the
intervention group differ from what will be observed in
the standard group. We choose the design of a non-infer-
iority trial to show that a reduced duration of antibiotic
therapy (superiority aspect) doesn’t change the outcome
(recurrence of infection, mortality).
As this trial will focus on the effectiveness and safety
of a Procalcitonin-guided antibiotic treatment, it will not
focus on the clinical reasons why a clinician will decide
to start antibiotics. The start of antibiotic treatment is
solely the decision of the attending neonatologist. The
purpose of the choice to not interact with this clinical
decision is to evaluate current clinical practice the clo-
sest without creating a bias towards biomarker started
(or withheld) therapy. Therefore, when designing this
intervention study, the definition of sepsis is less crucial
than in an observation study, because in an intervention
study all newborns are suspected to have bacterial infec-
tion and are therefore treated with antibiotics. The key
point is the comparison of the outcomes after interven-
tion. The probability of infection must be assessed by
the attending physician at t = 24-72 h during the hospi-
talisation, because antibiotic treatment is not discontin-
ued in neonates with proven or a high risk of infection
based on maternal risk factors, clinical signs and symp-
toms, and conventional laboratory parameters.
Benefit of the study is a possible limitation of unne-
cessary use of antibiotics. On a population level, unne-
cessary long-term use of broad-spectrum antibiotics is a
serious concern because it can promote the develop-
ment of resistant bacteria, which will result in untreata-
ble infections over time. Because the treatment consists
of intravenously administered antibiotics, this means
admission to the hospital for the neonate with separa-
tion of mother and child during these important first
days of life. It is obvious that shortening this period
when possible is desirable. It will also result in fewer
painful punctures. Neonates need punctures for new
intravenous lines very frequently, so shorter treatment
will result in fewer punctures.
The burden of the trial is minimal, because only one
extra time point for blood drawing will be done. For the
other time points no additional diagnostic procedures
are needed. The additional burden consists of a couple
of extra blood drops during routine blood sampling.
The estimated risk is low. There is a low risk on discon-
tinuing antibiotic treatment too early, resulting in the
development of a neonatal infection with its morbidity
and mortality. Based on follow-up data of our first study
no mortality was observed in 121 neonates [47]. In only
two children antibiotic treatment was restarted with good
outcome and without proof for secondary infections due
to early stop of primary antibiotic therapy.
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